Publication Khan Chachar AZ, Int J Sci (2020) (published paper)
Funding: No specific funding
Conflict of interest: *
Single center / Pakistan |
Follow-up duration (days): 7
12mg PO followed by 12 mg after 12 hours and 12mg after 24 hours
|Characteristics of participants|
Mean age : NR
Severity : Mild: n= 50/ Asymptomatic: n=0
Number of vaccinated participants: NR
|In the register|
1.Resolution of symptoms [ Time Frame: 7 days ]
Will look for resolution of Fever, Fatigue, myalgias, cough and we had an questionaire for that as well and followed up on their chest x rays for progression of the disease
Progression of the disease [ Time Frame: 14 days ]
did the disease progress from mild to moderate severity, like follow up chest x ray showed more infiltrates or their oxygen saturations in % dropped from their baseline and baseline symptoms persisted and got worse
|In the report|
Improvement of symptoms like Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue at day 7.
Yes. In English
Data-sharing willing stated in the publication:
|Risk of bias
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
In addition to all available versions of the published/pre-print article, the study registry and protocol were used in data extraction and risk of bias assessment. The target sample size specified in the registry was achieved.There is no change from the trial registration in the intervention. The outcome "Progression of the disease [ Time Frame: 14 days ]" was mentioned in the register but not reported.
This study was updated on February 9th, 2021 after contact with authors.